Faslodex Specific Clinical Experience Investigation

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01501266

D6997C00008

Details and patient eligibility

About

The purpose of this study is to confirm the safety profile such as the frequency of serious adverse events or any unexpected adverse events and overall efficacy of Faslodex for long term treatment in daily clinical practice.

Full description

MC MD

Enrollment: 660 estimated patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated with Faslodex for the first time due to postmenopausal breast cancer

Exclusion criteria

• None

Trial design

660 participants in 1 patient group

Faslodex